# Execution Output: phase5-package101-analysis-set-boundary-20260830 - worker_04

## Boundary And Context Check

- Read:
  - `context/phase5-package101-analysis-set-boundary-20260830_execution_context.md`
  - `plans/codex_execution_phase5-package101-analysis-set-boundary-20260830.md`
- Reviewed only the declared frozen plan, coverage manifest, freeze metadata, official-control matrix, package-100 contract/test pattern, replay implementation, and deterministic gates.
- No frozen baseline, protocol source, production source, or generated acceptance artifact was modified.
- No package-101 config, checklist, or test draft was present in the searched closure directory. This report therefore reviews the proposed contract shape against the package-100 pattern and frozen package-101 evidence; it does not claim package-101 implementation acceptance.

## Work Performed

### 1. Deterministic contract recommendation

Package 101 should use the following exact source partition:

```text
owned_source_refs:
  body.p1179
  body.p1186
  body.p1187
  body.p1188
  body.p1189
  body.p1190
  body.p1191
  body.p1192
  body.p1193
  body.p1194
  body.p1195
  body.p1196

attached_source_refs:
  body.p1180
  body.p1181
  body.p1182
  body.p1183
  body.p1184
  body.p1185
```

Required zero-candidate fields:

```text
required_candidate_source_refs: []
pre_enrollment_source_refs: []
expected_workflow_stage_ids_by_source_ref: {}
known_targets.official_rules: []
known_targets.required_procedures: []
claims_complete: false
```

Recommended structural-only owned refs:

```text
body.p1179
body.p1186
body.p1187
body.p1193
body.p1194
```

Recommended non-structural disposition expectations:

```text
body.p1188: administrative_statistical_background
body.p1189: administrative_statistical_background
body.p1190: administrative_statistical_background
body.p1191: administrative_statistical_background
body.p1192: administrative_statistical_background
body.p1195: administrative_statistical_background
body.p1196: administrative_statistical_background
```

`forbidden_candidate_source_refs` should contain all 18 declared owned and attached refs. Attached refs are read-only context and must never become candidate sources.

Recommended batching mode: `single_batch_with_known_targets`, retaining the package-100 implementation pattern. The batch should contain 12 owned units and 6 read-only attached units.

### 2. Clinical semantic closure

#### Sample-size design

- `body.p1181` is Phase II dose-exploration design background:
  - primary endpoint: Week 12 PASI-75 response proportion;
  - no formal hypothesis test for sample-size estimation;
  - two dose groups plus placebo;
  - planned randomization ratio 1:1:1;
  - approximately 40 participants per group and approximately 120 total.
- These are study-level design parameters, not participant-level pre-screen, screening, baseline, or D1 qualification rules.
- Preserve approximation qualifiers such as “预计” and “约”; do not convert the plan into an exact quota or enrollment gate.

#### Phase III context

`body.p1182-p1185` must remain attached, read-only Phase III context:

- `body.p1183`: Phase III superiority design, PASI-75, 2:1 allocation, 201 completers, one-sided alpha 0.025, 99% power.
- `body.p1184`: Phase III PGA-TS assumptions and 99% power.
- `body.p1185`: maximum 420 participants, 20% dropout assumption, 2:2:1 allocation, 168/168/84 planned caps.

These values must not be imported into the Phase II package. The source contains numerical assumptions that should be preserved literally rather than recomputed or silently reconciled. In particular, `body.p1184` contains both a 43.2% meta-analysis difference and a later 47.4% assumed difference. That is source content, not a basis for correction or candidate generation.

#### Analysis-set definitions

`body.p1188-p1191` describe post-randomization analysis populations:

- ITT: all randomized participants, analyzed according to randomized treatment; primary population for demographics, baseline, and efficacy.
- SS: randomized, at least one study-drug dose, and post-dose safety evaluation; analyzed by actual treatment.
- PKCS: randomized, at least one CMS-D001 dose, and at least one valid post-dose CMS-D001/major-metabolite concentration result where applicable.
- PDS: randomized, at least one study-drug dose, and at least one valid post-dose PD result.

These are analysis-set membership definitions. They do not require:

- randomization before screening;
- first dose before D1 qualification;
- post-dose safety, PK, or PD data before enrollment;
- study-drug exposure for every randomized participant;
- any missing analysis-set field to be treated as an eligibility failure.

#### Blind review and database timing

`body.p1192` states that Phase II and Phase III basic-period analysis-set partitions and exclusion lists are determined:

1. after blinded data review; and
2. before database lock and unblinding.

This is statistical data-management timing, not a participant-facing workflow obligation. The exact chronology must remain intact. It must not be inverted into:

- SAP approval before randomization;
- analysis-set completion before first dose;
- a screening or baseline evidence requirement;
- “unblinding before review”;
- “missing analysis-set membership means do not enroll.”

#### General statistical methods

- `body.p1195` specifies SAS 9.4 or later for efficacy/safety analyses and WinNonlin 8.1 or later for PK parameters.
- `body.p1196` specifies descriptive-statistic fields and current MedDRA/WHO Drug coding.
- These are statistical software, coding, and reporting background. They do not form participant-level controls or required screening/baseline procedures.

### 3. Required scope boundaries

The package-101 prompt must not absorb:

- package 100 statistical-hypothesis content: `body.p1168-p1178`;
- package 99 pregnancy content: `body.p1158-p1167`;
- package 102 statistical-analysis content: `body.p1197-p1205`.

The frozen package object contains `body.p1198` and `body.p1199` as broader context units even though they are not package-102 owned units. Under this assignment’s strict boundary, they should not be included in package-101 `attached_source_refs` or prompt material.

The package-101 prompt should include only the six declared attached refs `body.p1180-p1185`, not every context unit present in the frozen package object.

### 4. Invariants that must be locked

1. **Package identity**
   - plan ID remains `papl-e17d498106b6f71f440ff2be`;
   - package ordinal is `101`;
   - package ID is `pap-b0e90038f781b39606b42df9`;
   - selected phase is `phase_ii`;
   - manifest and snapshot IDs remain paired with the frozen plan.

2. **Exact ownership**
   - package 101 owns exactly `body.p1179` and `body.p1186-p1196`;
   - every owned ref appears once;
   - `body.p1179` remains owned by package 101 even though it appears as package-100 context;
   - package 102-owned refs remain outside package 101.

3. **Owned/context disjointness**
   - no structure-unit ID appears in both owned and attached sets;
   - attached units are read-only and cannot receive dispositions or candidates.

4. **Source-order closure**
   - replay output is sorted by frozen `source_order`, not by config-list order;
   - expected prepared-row order is `p1179`, `p1180-p1185`, then `p1186-p1196`.

5. **Phase separation**
   - `p1180/p1181` remain `phase_ii`;
   - `p1182-p1185` remain `phase_iii` context;
   - `p1192` remains `mixed`;
   - `p1179` and `p1186-p1196` retain their frozen `unknown`/`mixed` scopes;
   - `study_phase=phase_ii` on the selected manifest must not be confused with `phase_scopes`.

6. **Structural labels**
   - `p1179`, `p1186`, `p1187`, `p1193`, and `p1194` cannot become clinical controls;
   - no official eligibility, required procedure, or other-control candidate may cite them.

7. **No workflow binding**
   - no source maps to `flow-screening`, `flow-baseline`, or `flow-d1-pre-dose`;
   - no source is marked pre-enrollment;
   - no official or required-procedure target is attached.

8. **Analysis-set directionality**
   - ITT/SS/PKCS/PDS criteria remain post-randomization analysis definitions;
   - “at least one dose” and “post-dose data” must not become D1 or screening obligations;
   - actual-treatment analysis for SS must not be changed to randomized-treatment analysis.

9. **Blind-review chronology**
   - `盲态数据审核后` must precede determination;
   - determination remains before `数据库锁库和揭盲`;
   - no pre-randomization, pre-dose, or enrollment inversion.

10. **Statistical-method fidelity**
    - SAS and WinNonlin names and minimum versions remain attached to their respective analysis domains;
    - MedDRA and WHO Drug coding remains statistical-method context;
    - descriptive statistics must not become baseline procedure requirements.

11. **Zero-candidate state**
    - `required_candidate_source_refs=[]`;
    - accepted hydrated output must have zero candidates and zero candidate drafts;
    - every owned unit still receives exactly one non-candidate disposition;
    - no attached unit receives a disposition;
    - `claims_complete=false`.

12. **Boundary exclusion**
    - prompt and prepared source rows contain none of `body.p1197-p1205`;
    - package-100 and package-99 refs are absent;
    - source closure must fail or test must fail if any later-package source leaks into the prompt.

13. **Source integrity**
    - protocol SHA, plan SHA, coverage-manifest SHA, and structure-blob SHA remain fixed;
    - source excerpts are compared against frozen text, not regenerated or normalized.

### 5. Minimum deterministic test coverage

A focused package-101 test should contain at least the following assertions.

1. **Exact config contract**
   - owned and attached arrays exactly match the lists above;
   - structural-only list exactly matches the five headings;
   - required candidates, pre-enrollment refs, official targets, procedures, and expected workflow bindings are empty;
   - expected dispositions contain only the seven semantic owned refs.

2. **Frozen package ownership**
   - plan ID and package-101 ID match frozen values;
   - owned units equal the exact 12 refs in source order;
   - package context contains `p1180-p1185`;
   - owner map assigns `p1179` and `p1186-p1196` to package 101;
   - no `p1197-p1205` ref is owned by package 101.

3. **II/III phase graph**
   - assert `p1180/p1181` are Phase II;
   - assert `p1182-p1185` are Phase III;
   - assert no Phase III sample-size ref is in owned targets;
   - assert `p1192` is mixed.

4. **Critical excerpt preservation**
   - `p1181`: “剂量探索”, “不做正式的假设检验”, `1:1:1`, `每组纳入40例`, `合计约120例`;
   - `p1183`: `2:1`, `201例`, `α=0.025`, `99%`, and Phase III wording;
   - `p1184`: both `43.2%` and `47.4%` literal values;
   - `p1185`: `20%`, `最多入组420例`, `2:2:1`, `168例`, `84例`;
   - `p1188-p1191`: randomized/post-dose/valid-data/actual-treatment markers;
   - `p1192`: exact “盲态数据审核后” and “数据库锁库和揭盲之前” chronology;
   - `p1195`: SAS 9.4 and WinNonlin 8.1 thresholds;
   - `p1196`: descriptive-statistic fields, MedDRA, and WHO Drug.

5. **Dry-run source closure**
   - expected counts: `12 owned / 6 attached / 18 total`;
   - `claims_complete=false`;
   - lookup identity:
     - `p1179` and `p1186-p1196`: frozen-plan owned;
     - `p1180-p1185`: frozen-plan context;
   - source rows are source-order sorted;
   - prompt contains all 18 declared refs;
   - prompt excludes package-99, package-100, and `p1197-p1205`.

6. **Workflow and target absence**
   - no known official rules;
   - no known required procedures;
   - no pre-enrollment structure IDs;
   - no expected workflow-stage mappings;
   - no visit-instance mappings.

7. **Statistical-to-eligibility inversion resistance**
   - config and QC notes explicitly prohibit:
     - “至少一次给药是入组条件”;
     - “随机前完成分析集”;
     - “盲态审核为筛选必做”;
     - “缺少ITT/SS/PKCS/PDS不得入组”;
     - “数据库锁定前”改写为“入组前/给药前”.
   - candidate-forbidden markers should cover common screening/baseline/eligibility labels without using those markers as a substitute for source-specific semantic checks.

8. **Immutable fingerprints**
   - plan SHA: `92c7d179428216cfd4c9a47f2636bc7d7cfa8311025100d72dcb299e2f977fa4`;
   - structure SHA: `3946ea2c9780d0399b60245eafc4ab85087328a5da158b9d0938f8858302343d`;
   - coverage-manifest SHA: `affd0c907b47855914b72f09aa9f86e801a7a735b60ede923dcb991601a9aa75`;
   - source document SHA: `362443131f0d384c82c80f6a37396084f7d3301b51162201749c0488b0f2dd98`.

9. **Hydrated zero-candidate fixture**
   - If a hydrated replay test is added, construct all 12 owned dispositions exactly once with zero candidates/drafts.
   - Verify that adding a candidate for any owned unit produces a deterministic rejection.
   - Verify that attached or out-of-batch structure IDs produce scope rejection.
   - A dry-run alone must remain marked as gate-skipped and must not be reported as hydrated acceptance.

## Artifacts And Evidence

- Frozen plan:
  - `artifacts/phase5-slice61cm-d001-phase-context-boundary-rebaseline-20260830/frozen_phase_plan.json`
  - 131 packages, package 101 present with 12 owned units.
- Package 101 frozen identity:
  - package ID: `pap-b0e90038f781b39606b42df9`;
  - package ordinal: `101`;
  - selected phase: `phase_ii`;
  - protocol version: `D001-02-002:v1.0:phase-ii`;
  - snapshot: `d001-ii-phase-closure-20260830-slice61cm-phase-context-boundary-rebaseline-snapshot`.
- Coverage manifest:
  - `artifacts/phase5-slice61cm-d001-phase-context-boundary-rebaseline-20260830/coverage_manifest.json`;
  - 1848 coverage units;
  - `claims_full_coverage=false`.
- Freeze metadata:
  - `artifacts/phase5-slice61cm-d001-phase-context-boundary-rebaseline-20260830/freeze_metadata.json`;
  - source unchanged flag is `true`;
  - source SHA and structure SHA match the frozen values above.
- Official-control matrix:
  - `.trellis/tasks/08-22-phase5-clinical-facts-profile/research/d001-ii-official-flow-controls.json`;
  - 58 rows;
  - none of `body.p1179-p1196` appears in official source anchors.
- Package-100 template:
  - `.../configs/representative_group_package100_statistical_hypothesis_phase_boundary.v1.json`;
  - `.../test_slice61cm_package100_statistical_hypothesis_phase_boundary.py`;
  - existing pattern uses zero required candidates, empty official/procedure targets, structural-only refs, prompt source closure, phase separation, anti-inversion checks, and immutable plan/structure fingerprints.
- Replay implementation reviewed:
  - `.../slice59n_representative_group_control_replay.py`;
  - confirmed that hydrated results must disposition every owned unit exactly once;
  - attached units remain outside owned disposition scope;
  - dry-run writes only preparation evidence and skips hydrated publication gates.
- Deterministic gates reviewed:
  - `.../slice59n_representative_group_reject_gates.py`;
  - confirmed scope, phase, forbidden-candidate, expected-disposition, and workflow-stage checks.

## Commands And Observations

- `functions.glob` over the package-101 closure directory:
  - found package-100 contract/test/checklist and earlier package contracts;
  - found no package-101 config, test, or checklist draft.
- Python JSON inspection of `frozen_phase_plan.json`:
  - package count: 131;
  - package 101 owned refs: `p1179`, `p1186-p1196`;
  - package 101 context includes `p1180-p1185` and broader context units including `p1198/p1199`.
- Python inspection of `coverage_manifest.json`:
  - package-101 refs have unique structure-unit IDs and source orders;
  - `p1180/p1181` are Phase II;
  - `p1182-p1185` are Phase III;
  - `p1192` is mixed;
  - analysis-set and general-method paragraphs are frozen with `unknown` phase scope.
- Python inspection of official matrix:
  - no official matrix source anchor overlaps `body.p1179-p1196`.
- Python SHA-256 inspection:
  - verified plan, coverage manifest, structure blob, freeze metadata, and official matrix fingerprints.
- No pytest or replay command was run:
  - no package-101 executable draft exists yet;
  - replay dry-run writes preparation artifacts;
  - this worker was restricted to read-only contract review and must not create or modify runner artifacts.

## Blockers Or Missing Environment

- **Blocking for execution acceptance:** package-101 config/test/checklist artifacts are not yet present in the searched closure directory.
- No missing interpreter or package environment was encountered.
- No hydrated Agent output exists for package 101, so candidate-count, full-disposition, publication-gate, and parent clinical acceptance cannot be verified here.
- This review does not constitute clinical, regulatory, publication, or final parent acceptance.

## Rerun Requests Or Next Step

1. Create package-101 config with the exact owned/attached/structural partition and zero-candidate fields above.
2. Create the focused package-101 test, including the package-102 prompt exclusion and post-randomization analysis-set inversion cases.
3. Run the dry-run replay and verify `12/6/18`, source-order sorting, lookup identities, `claims_complete=false`, and absence of `p1197-p1205`.
4. Run the focused test with the repository `.venv` interpreter.
5. If a live replay is later authorized, require all 12 owned dispositions, zero candidates, zero workflow bindings, and deterministic gate output before Codex performs clinical review.
